Antifungal Drugs Market Size (2024 - 2029)

Antifungal Drugs Market Analysis

The Anti-fungal Drugs Market size is estimated at USD 16.61 billion in 2024, and is expected to reach USD 20.11 billion by 2029, growing at a CAGR of 3.9% during the forecast period (2024-2029).

The major factors contributing to the growth of the anti-fungal drugs market include increased awareness of many fungal infections, rising numbers of over-the-counter (OTC) anti-fungal drugs, and increased use of antimicrobial drugs in developing countries. The growing popularity of OTC drugs such as clotrimazole, econazole, ketoconazole, miconazole, and amorolfine has resulted in many patients using OTC drugs.

An increase in onychomycosis cases, a fungal infection of the fingers and toes, is also expected to contribute to the market’s growth. For instance, according to the data updated by the CDC in September 2022, onychomycosis affected up to 14% of the general population in the world, and fungal toenail infections became more common than fungal fingernail infections.

Additionally, excessive glucose can lead to high cellular damage, resulting in several infectious and non-infectious skin disorders. Therefore, diabetes patients are more susceptible to various fungal infections, and onychomycosis is one of the major infections among the target population. For instance, according to an article published in the Journal of Fungi in August 2022, when a group of people was studied for skin and nail disorders in diabetic patients, onychomycoses were found common in critically ill diabetic patients.

Furthermore, the same study stated that dermatophytes were found to be the commonest cultural isolates (50%), followed by yeasts and molds in 30.8% and 19.2%, respectively, of the diabetes patients. Hence, the high burden of diseases among the target population is expected to increase the demand for antifungals and contribute to the overall growth of the market studied over the forecast period.

Moreover, the increasing focus of companies on adopting key strategic activities such as product launches, mergers and acquisitions, collaborations, and partnerships is further expected to boost the availability of anti-fungal drugs in the market over the forecast period. For instance, in June 2022, Apex Labs introduced the advanced Supra Bioavailable Itraconazole 65 and 130 mg capsules, a potent therapeutic option for effectively controlling fungal infections. Supra Bioavailable Itraconazole capsules deliver a higher percentage (90%) of active medicine to the biological system at a lesser dose. This advanced preparation also ensures lesser inter-individual variability, which may translate into enhanced efficacy in the management of fungal infections, according to a statement from the company.

Thus, the growing incidence of fungal infection and strategic activities adopted by market players is expected to contribute to market growth over the forecast period. However, increasing resistance to anti-fungal drugs and the side effects of these drugs are anticipated to hinder their adoption and demand, thereby restraining the market's growth.

Antifungal Drugs Industry Segmentation

As per the scope of this report, anti-fungal drugs are used/prescribed for the treatment of diseases caused by fungi. The anti-fungal drugs market is segmented by drug type, indication, dosage form, and geography. By drug type, the market is segmented as echinocandins, azoles, polyenes, allylamines, and other drug types. By indication, the market is segmented as aspergillosis, dermatophytosis, candidiasis, and other indications. By dosage form, the market is segmented as powder, ointments, tablets, and other dosage forms. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (USD) for the above segments.